Clinical Oncology Research Articles

Psychometric Properties of the Generalized Anxiety Disorder Scale (GAD-7) in Older Adults With Advanced Cancer.

Over half of new cancer diagnoses occur in patients aged 65 or older, with up to 40% experiencing anxiety. The American Society of Clinical Oncology recommends using the Generalized Anxiety Disorder Scale (GAD-7) for anxiety screening, but the GAD-7 psychometric properties in this population are unknown. This study examined the GAD-7's reliability, validity, and item parameters, comparing its utility with the GAD-2 in older adults with cancer. This cross-sectional secondary analysis of a nationwide multi-site two-arm cluster randomized trial in older adults (≥70)with advanced cancer. The GAD-7 was administered at baseline. Properties were evaluated with Cronbach's α, Pearson correlation coefficients, and a 2-parameter logistic model. Logistic regression models compared the GAD-2 and GAD-7. The sample included 718 participants (Mean age=77, SD=5) with mild anxiety (M=3.74, SD=4.74). Internal consistency was strong (Cronbach's alpha=0.89) and item-total correlations ranged 0.53 to 0.78. Item 2 (Not being able to stop or control worrying) was the most discriminating and item 5 (Being so restless that it is hard to sit still) was least discriminating. Area Under the Curve (AUC) analyses demonstrated the GAD-2 had a 0.93-0.96 AUC. Establishing the psychometric properties of anxiety screening measures is crucial in the older adults with cancer to maximize referral efficiency and accuracy. This study indicates that the GAD-7 is reliable and valid for older adults with cancer. Analyses suggest the GAD-2 may be as sufficient as the GAD-7 in identifying anxiety in older adults with cancer, thereby reducing assessment burden.

An Integrative Review of the Effectiveness of Duloxetine Use in Cancer Patients Receiving Chemotherapy

Purpose: The objective of this Integrative Review of Literature (IRL) was to assess the efficacy of duloxetine in the management of chemotherapy-induced peripheral neuropathy (CIPN) among cancer patients. Peripheral neuropathy associated with chemotherapy manifests as symptoms such as tingling, burning, numbness, weakness, or pain in the hands and feet. The detrimental and, in some cases, debilitating impact of CIPN on individuals undergoing cancer treatment underscores the significance of investigating the effectiveness of duloxetine as part of the treatment plan for this condition. Procedure: A comprehensive literature search was performed to identify peer-reviewed journal articles on the effectiveness and safety of the use of duloxetine for the treatment of CIPN. The search was conducted using two electronic databases: CINHAL and PubMed. Additional supplemental sources, including the American Cancer Society, American Society of Clinical Oncology, Google Scholar, and Medline, were used to compile additional information for review. Results: The strengths and weaknesses of each article were reviewed utilizing the Johns Hopkins Research Appraisal tool. A data synthesis review exhibited good to high-quality articles with a range of evidence, including Level I, Level II, and Level III. Research yielded positive outcomes in reducing pain, increasing quality of life, and reducing the severity of symptoms for both physical and mental health with Duloxetine treatment. Results showed effectiveness and tolerability in the treatment of CIPN. Adding Duloxetine to the CIPN treatment plan positively impacted pain management and enhanced quality of life (QoL). Conclusion: Studies revealed that Duloxetine, as a pharmacologic intervention, resulted in a reduction in pain and an improvement in the quality of life (QoL) for patients experiencing chemotherapy-induced peripheral neuropathy (CIPN). Duloxetine demonstrated enhanced effectiveness, safety, and tolerability in its outcomes. Notably, the American Society of Clinical Oncology has designated Duloxetine as the standard of care for CIPN. Given its status as the standard of care, there is a higher likelihood of favorable considerations for Duloxetine by insurance companies.

A Comparison of Palliative Care Perceptions Across Metastatic Spine Patients and the General Population.

Background: Palliative care (PC) has been shown to benefit patients with metastatic cancer by managing symptoms, improving quality of life, and facilitating advance care planning. Despite this, PC is often misunderstood and underutilized. Objective: To deepen our understanding of PC barriers seen among the spine metastasis population. Design/Setting: Between March 2021 and August 2022, people with metastatic spine tumors (MSTs) at a multidisciplinary oncology clinic were administered a survey on PC prior to their scheduled appointment. These responses were compared with the Health Information National Trends Survey 5 (HINTS 5), which is a validated survey created by the National Cancer Institute between February and June of 2020. Chi-squared statistical analysis was used. Results: Fifty-six people with MST were compared with 3795 patients from the HINTS 5 database. People with MST reported a significantly higher baseline understanding of PC when compared with the general population (GP) (chi-squared = 34.4, p = <0.0001). People with MST had a higher frequency of disagreement with the statement "PC is equivalent with death" when compared with the GP (chi-squared = 12.8, p = 0.0124). Over 25% of the MST group reported no understanding of PC. Conclusion: MST patients are often referred to PC services due to the extreme symptom burden of their disease. Based on this study, in comparison to the GP, people with MST tended to have a more accurate and well-adjusted perception of the goals and functions of PC. Although reassuring, there remains a high proportion of patients who have no knowledge of PC, and groups erroneously associated PC with hospice status.

Modulating the organization of medical care and early diagnosis of prostate cancer

Aim. To analyze the existing system of medical care organization and timely diagnostics for prostate cancer (PC).Materials and Methods. The study utilized data from official statistics to analyze the system of medical care organization and the diagnostic methods applied for prostate cancer at different stages.Results. In the country, medical care for patients with prostate cancer is organized into three levels. The first level involves family physicians, urologists, and oncologists in oncology clinics, where access to modern diagnostic facilities is limited. The second level provides advanced diagnostic services through regional oncology centers and major urology departments. The third level offers specialized care at the National Cancer Research Center (NCRC) and select urology clinics. Based on the experience of other countries, it is recommended to improve the system of medical care for prostate cancer by establishing four stages of care. The proposed model takes into account the real situation, emphasizing the need for prevention, timely diagnosis, and effective treatment in accordance with clinical protocols, as well as the coordinated use of human and technological resources from oncology, urology, and morphological services at all stages.Conclusions. The proposed model for organizing medical care, based on evidence-based practices, aims to improve early detection of prostate cancer, enhance the clinical effectiveness of treatment, and optimize the use of resources.

Spiritual Well-Being of Cancer Patients Undergoing Chemotherapy in Yogyakarta

Background: In order to provide holistic care and advance spiritual well-being, it is essential to identify and meet the patient's spiritual well-being. Purpose: This study aimed to determine the spiritual well-being of cancer patients undergoing chemotherapy in Yogyakarta. Methods: This study used a cross-sectional approach with a sample of 50 cancer patients undergoing chemotherapy at the One Day Care (ODC) oncology clinic, a private hospital in Yogyakarta, which was taken using a purposive sampling technique. The measurement tool used is the Spiritual Well-Being Scale (SWBS) questionnaire which consists of 20 items. Data analysis in this study used descriptive statistics and cross tabulation to determine the comparison between spiritual well-being of cancer patients undergoing chemotherapy based on their demographic characteristics. Results: Spiritual well-being has a higher score in patients who are female (92.53±10.49), have higher education (92.67±10.84), are widowers/widows (97.00 ± 4.24), receive treatment of the partner (93.81 ± 10.30), and had stage III disease (92.88 ± 9.54). Conclusion: An accurate assessment of spirituality in patients can be a clinical guide in establishing nursing diagnoses of spiritual distress or readiness to improve spiritual well-being.

Real-world Referral Pattern of Unplanned Excision in Patients With Soft-tissue Sarcoma: A Multicenter Study Conducted by the Bone and Soft-tissue Tumor Study Group of the Japan Clinical Oncology Group.

Despite the well-publicized clinical outcomes after unplanned excision (UE) and re-excision (re-excision) in patients with soft-tissue sarcoma (STS), there is little information about the real-life referral patterns for UE, such as patient profile, details of procedures, and subsequent management after UE. We aimed to investigate the characteristics of patients with UE who were referred to sarcoma-specific centers. Between May 2022 and June 2023, we registered 97 patients who underwent UE and were referred to sarcoma-specific centers in Japan. We excluded those with well-differentiated liposarcomas and dermatofibrosarcoma protuberances. We investigated the details of UE and additional treatment after UE. There were 49 men and 48 women, with a mean age of 62 years. A broad range of surgeons performed UE; 36 plastic surgeons, 22 orthopedic surgeons, 17 general surgeons, 17 dermatologists, and 5 others. The mean tumor size was 4.1 cm. Local anesthesia was administered to 58 patients. Forty-five patients underwent UE without prior magnetic resonance imaging. Inappropriate transverse skin incisions were performed in 42 patients. Of the 97 patients, 82 underwent re-excision after UE. The mean time between UE and date of initial presentation at the referral hospital was 46 days. The mean interval between UE and re-excision was 96 days. Of the 82 patients, 59 underwent soft-tissue reconstruction after re-excision. A broad range of surgeons performed UE. Continuous education about STS should be considered for all surgeons. UE should be avoided because residual tumors are common, and reconstructive surgery may be necessary.

Three years Clinico-Epidemiological Study of Breast Cancer Patients at Clinical Oncology Department –Tanta University

Three years Clinico-Epidemiological Study of Breast Cancer Patients at Clinical Oncology Department –Tanta University

RE: A real-world survey on expensive drugs used as first-line chemotherapy in patients with HER2-negative unresectable advanced/recurrent gastric cancer in the stomach cancer study group of the Japan clinical oncology group.

RE: A real-world survey on expensive drugs used as first-line chemotherapy in patients with HER2-negative unresectable advanced/recurrent gastric cancer in the stomach cancer study group of the Japan clinical oncology group.

When molecular biology transforms clinical oncology: the EGFR journey in colorectal cancer.

The discovery of growth factors and their involvement in cancer represents the foundation of precision oncology. The preclinical and clinical development of agents targeting epidermal growth factor receptor (EGFR) in colorectal cancer (CRC) were accompanied by big hype and hopes, though the clinical testing of such agents clashed with intrinsic and acquired resistance, greatly limiting their therapeutic value. However, a better understanding of the biology of the EGFR signaling pathway in CRC, coupled with the development of liquid biopsy methodologies to study cancer evolution in real time, fostered the clinical refinement of anti-EGFR treatment in CRC. Such a workflow, based on the co-evolution of biology knowledge and clinical development, allowed to couple the discovery of relevant therapy resistance mechanisms to the development of strategies to bypass this resistance. A broader application of this paradigm could prove successful and create an effective shortcut between the bench and the bedside for treatment strategies other than targeted therapy.

Exploring the role of AI-driven chatbots in patient care: a critical evaluation amidst healthcare staff shortages

Abstract Background Amidst the backdrop of staff shortages in healthcare systems, patients and their families are increasingly turning to chatbots, powered by Large Language Models (LLMs), for information about their medical conditions. These AI-driven chatbots, capable of generating human-like responses across a broad range of topics, have become a prevalent tool in the healthcare landscape. Given the proliferation of these chatbots, it is crucial to evaluate the quality and accuracy of the responses they provide. Methods We selected five freely accessible chatbots (Bard, Microsoft Copilot, PiAI, ChatGPT, and ChatSpot) for our study. These chatbots were posed questions spanning three medical fields: cardiology, cardio-oncology, and cardio-rheumatology. The responses generated by the chatbots were then compared against established guidelines from the European Society of Cardiology, American Academy of Dermatology, and American Society of Clinical Oncology. In addition to the content, the readability of the responses was evaluated using four different readability scales: the Flesch Reading Scale, Gunning Fog Scale Level, Flesch-Kincaid Grade Level, and Dale-Chall Score. To assess the accuracy of the responses in accordance with the medical guidelines, two independent medical professionals rated them on a 3-point Likert scale (0 - incorrect, 1 - partially correct or incomplete, 2 - correct). This allowed us to gauge the compliance of the chatbot responses with the medical guidelines. Results Results: In our study, we posed a total of 45 questions to each of the chatbots. Out of the five chatbots, Microsoft Copilot, PiAI, and ChatGPT were able to respond to all the questions. The length of the responses varied, with PiAI providing the shortest average response length of 7.26 words, and Bard providing the longest at 18.9 words. In terms of readability, the Flesch Reading Ease Scale scores ranged from 17.67 (ChatGPT) to 39.34 (Bard), indicating the relative complexity of the responses. The Flesch-Kincaid Grade Level, which reflects the academic grade level required to comprehend the text, ranged from 14.02 (PiAI) to 15.97 (ChatGPT). The Gunning Fog Scale Level, another measure of readability, varied from 15.77 (Bard) to 19.73 (ChatGPT). Lastly, the Dale-Chall Score, which assesses the understandability of the text, ranged from 10.24 (Bard) to 11.87 (ChatGPT). These results highlight the variability in the readability and complexity of responses generated by different chatbots. Readability analysis is presented in table 1. Conclusion This study indicates that chatbots vary in length, quality and readability. They answer each question in their way, based on data they have pulled from the network. Our data suggests that people who want information from a chatbot need to be careful and verify the answers they get.

Expert consensus on integrated medicine for tumor-related gastric injury and protection in China (2024 edition)

Neoplasm is one of the major causes of harm to human health. With the development of integrated medicine, more experts have begun to pay attention to tumor-related damage, among which gastric injury is common and seriously affects the quality of life of patients. The stomach is richly supplied with blood and nerves. Tumor treatment methods such as medication, surgery, and interventional therapy can impair its barrier function. Additionally, the tumor itself can harm the stomach through various mechanisms, primarily manifesting as symptoms like gastritis, erosion, ulceration, bleeding, and perforation. These conditions significantly affect the patient's quality of life and pose a serious threat to life.At present, the mechanisms of gastrointestinal tumors and other systemic tumors causing gastric injury are unclear, and there is a lack of relevant clinical and basic research. The diagnostic criteria and protective measures need to be supplemented and improved. To enhance the understanding of tumor-related gastric injuries and their management among professionals in related fields and to guide clinical practice, this expert consensus has been refined and formulated under the integrated medical concepts and based on the previous guidelines of the Chinese Anti-Cancer Association (CACA). It summarizes various tumor-related gastric injuries and protective treatment strategies, aiming to provide clinicians in oncology with a reference to address and prevent gastric injuries during the treatment of systemic diseases, thereby laying a foundation for further in-depth research in the future.

Impact of a National Virtual Oncology Course on Medical Student Competency and Interest in Oncology.

Globally, surveys have identified that medical learners of all levels perceive their oncology instruction to be inadequate. To address these gaps, we systematically developed and implemented the Oncology National Course for Advocacy, Research, and Education (ONCARE), a novel, nationally organized virtual course available to all Canadian medical students and evaluated its impact on oncology competency and interest. ONCARE was designed utilizing Kern's Six-Step Model for Curriculum Development. Components of ONCARE included lectures, career panels, and a mentorship program. Pre-course and post-course survey responses were collected to determine course impact on oncology knowledge and interest. Between October 2023 and March 2024, ONCARE enrolled 235 students representing 14 Canadian medical schools. One hundred forty (60%) students enrolled reported having only 0 to 10h of formal oncology instruction. Baseline interest in a career in oncology was high (mean Likert score 3.9/5) and remained unchanged following course completion. ONCARE increased both self-perceived knowledge in clinical oncology (mean Likert score 3.9/5 vs 2.9/5, p < 0.001) and confidence in oncology communication skills (mean Likert score 3.6/5 vs 3.1/5, p < 0.001). Ninety-seven percent of students were satisfied with the course (mean Likert score 4.6/5). The implementation of ONCARE as a proof-of-concept initiative builds upon previous educational interventions in oncology and highlights important principles for the development of related initiatives. Future work will target greater interdisciplinary and multinational collaboration as well as long-term follow-up of the ONCARE cohort.

Update on HPV-associated head and neck cancers-highlights of the 2024 ASCO Annual Meeting

Human papillomavirus (HPV)-associated head and neck squamous cell carcinoma (HNSCC) is becoming increasingly important in head and neck oncology. At this year's conference of the American Society of Clinical Oncology (ASCO), alarge number of papers were presented on the topic of HPV-associated HNSCC, particularly with regard to neoadjuvant treatment approaches, radiation de-escalation strategies, therapeutic vaccines, and treatment monitoring. In this context, study results on the treatment of HPV-related recurrent respiratory papillomatosis (RRP) were also presented. Based on contributions to the 2024 ASCO Annual Meeting, an insight into the latest developments in HPV-associated diseases of the head and neck is provided. The papers were reviewed for clinical relevance and contextualized based on current therapeutic concepts. Alarge number of studies on liquid biopsies (LB) were presented. It was shown that although the methods for analyzing LBs for HPV-positive patients are well developed and can be used for diagnostics, risk classification, treatment management, or tumor follow-up, the methods vary considerably, and their clinical application has not yet been sufficiently validated. With regard to therapeutic HPV vaccination, three large studies were presented for the treatment of recurrent/metastatic HPV-positive oropharyngeal squamous cell carcinoma (OPSCC). The only randomized study was on the vaccine ISA101b (peltopepimut-S) and did not reach its primary endpoint; however, the vaccine seemed to be highly effective in patients with a combined positive score (CPS) ≥ 20. Furthermore, data from aphaseIstudy on PRGN2012, an adenovirus-based immunotherapy used therapeutically for the treatment of recurrent respiratory papillomatosis (RRP), were presented. PRGN2012 led to areduction in surgical interventions for RRP, and the US Food and Drug Administration (FDA) designated PRGN2012 as abreakthrough therapy and orphan drug. However, the vaccine is not yet approved for the treatment of RRP.

Clinical features and survival rate of patients with ovarian granulosa cell tumor in Iran; a 10-year retrospective study

IntroductionOvarian granulosa cell tumor (OGCT) is a rare female pathology with few available demographic data. Besides, there are no comprehensive clinical characteristics regarding the OGCT in Iran. Thus, this study aimed to assess the clinical features and survival rate of OGCT patients in Iran to expand the scope of knowledge in this field.Materials and methodsIn this 10-year retrospective study (2013–2023), the cases were gathered from the oncologic clinic of women (Imam Khomeini Hospital, Tehran, Iran). The patients with definite OGCT diagnosis were selected based on the inclusion and exclusion criteria including medical history, interfering backgrounds, demographic data, histopathological assessment, clinical and para-clinical features, survival rates, and all previous medical reports for definite diagnosis of OGCT along with approved pathology samples.ResultsThe median age and BMI values of Iranian patients were 45 (19 ~ 83) years and 28.04 (19.4 ~ 48.0), respectively. The most common symptom was abdominal pain (56%) and 69.2% of cases were menopause. In 81.3% of cases, ovarian tumors were detected and metastasis was rare. Most patients (40.6%) underwent total abdominal hysterectomy and OGCT relapsing cases were seen in 13.2% of patients. The median of overall survival (OS) value using the Kaplan-Meier estimate was 52 months (95%CI:37.47–66.53), and the median of disease-free survival (DFS) was 45 months (95%CI: 28.88–61.12). There was a significant (p < 0.05) relation between chemotherapy and left oophorectomy with OS. A significant (p < 0.05) correlation was also detected among the OGCT stage and left oophorectomy with DFS.ConclusionOS and DFS values showed that the OGCT in Iranian patients can be treated in most cases using two main procedures of chemotherapy and oophorectomy. Parallel application of both procedures and associated outcomes are suggested for future studies.

Deciphering the landscape of triple negative breast cancer from microenvironment dynamics and molecular insights to biomarker analysis and therapeutic modalities.

Triple negative breast cancer (TNBC) displays a notable challenge in clinical oncology due to its invasive nature which is attributed to the absence of progesterone receptor (PR), estrogen receptor (ER), and human epidermal growth factor receptor (HER-2). The heterogenous tumor microenvironment (TME) of TNBC is composed of diverse constituents that intricately interact to evade immune response and facilitate cancer progression and metastasis. Based on molecular gene expression, TNBC is classified into four molecular subtypes: basal-like (BL1 and BL2), luminal androgen receptor (LAR), immunomodulatory (IM), and mesenchymal. TNBC is an aggressive histological variant with adverse prognosis and poor therapeutic response. The lack of response in most of the TNBC patients could be attributed to the heterogeneity of the disease, highlighting the need for more effective treatments and reliable prognostic biomarkers. Targeting certain signaling pathways and their components has emerged as a promising therapeutic strategy for improving patient outcomes. In this review, we have summarized the interactions among various components of the dynamic TME in TNBC and discussed the classification of its molecular subtypes. Moreover, the purpose of this review is to compile and provide an overview of the most recent data about recently discovered novel TNBC biomarkers and targeted therapeutics that have proven successful in treating metastatic TNBC. The emergence of novel therapeutic strategies such as chemoimmunotherapy, chimeric antigen receptor (CAR)-T cells-based immunotherapy, phytometabolites-mediated natural therapy, photodynamic and photothermal approaches have made a significant positive impact and have paved the way for more effective interventions.

Large language model use in clinical oncology

Large language models (LLMs) are undergoing intensive research for various healthcare domains. This systematic review and meta-analysis assesses current applications, methodologies, and the performance of LLMs in clinical oncology. A mixed-methods approach was used to extract, summarize, and compare methodological approaches and outcomes. This review includes 34 studies. LLMs are primarily evaluated on their ability to answer oncologic questions across various domains. The meta-analysis highlights a significant performance variance, influenced by diverse methodologies and evaluation criteria. Furthermore, differences in inherent model capabilities, prompting strategies, and oncological subdomains contribute to heterogeneity. The lack of use of standardized and LLM-specific reporting protocols leads to methodological disparities, which must be addressed to ensure comparability in LLM research and ultimately leverage the reliable integration of LLM technologies into clinical practice.

Cancer Caregiver Anxiety Over Time: The Influence of Palliative Care.

Objectives: To explore anxiety experienced by caregivers providing home-based, end-of-life care to patients with cancer. We examined the relationship between caregiver anxiety and receipt of palliative care by the patient. Methods: A case series of terminal cancer patient-caregiver dyads (n = 223) were recruited from oncology clinics in Virginia and Pennsylvania and followed for 12 months or until patient death. Data collected included qualitative, quantitative, and observational data; this analysis utilizes the quantitative data. Longitudinal Latent Growth Models were used to characterize the heterogeneity of primary caregiver anxiety over time. The influence of palliative care on caregiver anxiety over time was assessed. Characteristics associated with membership in the trajectory groups rendered from those models are presented. Results: The majority of caregivers were female (73.9%), white (54.9%), and patient spouses (45.3%). Three classes of caregivers were identified based on their anxiety scores over time (low, elevated, and high). The 2 groups who had elevated and high anxiety had significant increases in anxiety over time. Controlling for patient receipt of palliative care attenuated those increases. Caregivers with the lowest level of anxiety were more likely to be Black, report fewer symptoms of depression or caregiver burden and higher self-rated physical health. Caregivers who were younger reported higher anxiety. Conclusions: Our analysis detected 3 distinct cancer caregiver groups reporting low, elevated, and very high levels of anxiety. Caregivers with elevated or high anxiety also demonstrated increasing anxiety overtime; however increases were attenuated with patient receipt of palliative care. For cancer caregivers with elevated and high levels of anxiety, palliative care buffers further deterioration of their mental health.

Ivosidenib (Tibsovo)

We recommend that Tibsovo in combination with azacitidine be reimbursed by public drug plans for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) with an IDH1 R132 mutation who are not eligible to receive intensive induction chemotherapy, if certain conditions are met. Tibsovo in combination with azacitidine should only be covered to treat adult patients with newly diagnosed AML with an IDH1 R132 mutation who are considered ineligible for standard intensive induction chemotherapy and are aged at least 75 years; have an Eastern Cooperative Oncology Group (ECOG) performance status of 2; have severe organ dysfunction in the heart, lungs, kidneys, or liver; and/or have any other comorbidity judged to be incompatible with intensive induction chemotherapy. Tibsovo in combination with azacitidine should only be reimbursed if prescribed by clinicians with expertise in managing patients with AML in a specialized hematology or oncology clinic, and the treatment should be supervised and delivered in institutions with expertise in systemic therapy delivery. The total drug cost of ivosidenib plus azacitidine should not exceed that of venetoclax plus azacitidine. Lastly, it must be feasible to test patients for IDH1 R132

Performance of Multimodal Artificial Intelligence Chatbots Evaluated on Clinical Oncology Cases

Multimodal artificial intelligence (AI) chatbots can process complex medical image and text-based information that may improve their accuracy as a clinical diagnostic and management tool compared with unimodal, text-only AI chatbots. However, the difference in medical accuracy of multimodal and text-only chatbots in addressing questions about clinical oncology cases remains to be tested. To evaluate the utility of prompt engineering (zero-shot chain-of-thought) and compare the competency of multimodal and unimodal AI chatbots to generate medically accurate responses to questions about clinical oncology cases. This cross-sectional study benchmarked the medical accuracy of multiple-choice and free-text responses generated by AI chatbots in response to 79 questions about clinical oncology cases with images. A unique set of 79 clinical oncology cases from JAMA Network Learning accessed on April 2, 2024, was posed to 10 AI chatbots. The primary outcome was medical accuracy evaluated by the number of correct responses by each AI chatbot. Multiple-choice responses were marked as correct based on the ground-truth, correct answer. Free-text responses were rated by a team of oncology specialists in duplicate and marked as correct based on consensus or resolved by a review of a third oncology specialist. This study evaluated 10 chatbots, including 3 multimodal and 7 unimodal chatbots. On the multiple-choice evaluation, the top-performing chatbot was chatbot 10 (57 of 79 [72.15%]), followed by the multimodal chatbot 2 (56 of 79 [70.89%]) and chatbot 5 (54 of 79 [68.35%]). On the free-text evaluation, the top-performing chatbots were chatbot 5, chatbot 7, and the multimodal chatbot 2 (30 of 79 [37.97%]), followed by chatbot 10 (29 of 79 [36.71%]) and chatbot 8 and the multimodal chatbot 3 (25 of 79 [31.65%]). The accuracy of multimodal chatbots decreased when tested on cases with multiple images compared with questions with single images. Nine out of 10 chatbots, including all 3 multimodal chatbots, demonstrated decreased accuracy of their free-text responses compared with multiple-choice responses to questions about cancer cases. In this cross-sectional study of chatbot accuracy tested on clinical oncology cases, multimodal chatbots were not consistently more accurate than unimodal chatbots. These results suggest that further research is required to optimize multimodal chatbots to make more use of information from images to improve oncology-specific medical accuracy and reliability.

Unveiling the Landscape of Brazilian Clinical Oncologists: Challenges, Diversity, and Quality Care

AbstractCancer remains a significant public health challenge in Brazil, with an estimated 704 thousand new cases annually. Clinical oncology, a pivotal specialty in cancer diagnosis and treatment, has evolved since its formal establishment in 1946. Recent recognition by the Brazilian Federal Board of Medicine solidified its status, culminating in normative resolution nr. 2,162/2017. The present study aims to characterize Brazilian clinical oncologists and analyze their epidemiological and structural contexts using data from the Brazilian Society of Clinical Oncology's 2023 census and secondary sources, including the National Cancer Institute (Instituto Nacional de Câncer [INCA], in Portuguese) and Brazilian Institute of Geography and Statistics (Instituto Brasileiro de Geografia e Estatistica [IBGE], in Portuguese). A cross-sectional design employing qualitative-quantitative methods surveyed 761 clinical oncologists, revealing insights into demographics, workload, stress levels, and challenges. The results highlight regional disparities in cancer mortality rates despite the concentration of oncology services in the South and Southeast. Challenges include access to new treatments, late diagnoses, and systemic underfunding. Moreover, this study underscores gender and racial disparities within the specialty, indicating a predominantly white and heterosexual profile among practitioners. Addressing these issues is crucial for enhancing healthcare equity and improving patients' outcomes in oncology practice.